Elba Medina

A Skit we performed for Women In Nephrology (WIN-ICON) India conference at Chennai in Sep 2025.

Up next!

CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC

pubmed.ncbi.nlm.nih.gov/40876553/

#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression? — NephJC This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘.
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334

NephJC 2025 Fall Pledge Drive — NephJC Help keep NephJC a vital, original, and unbiased source of medical education.

It's that time of year again 🍂🍂🍂
The #NephJC Fall pledge drive.
Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky
www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive

1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed about AHA/ACC 2025 Hypertension guidelines: PREVENT, Detect, Treat
Didn’t catch the pulse of this one? No worries we’ll help you pressure check the 2025 AHA Hypertension Guidelines. ❤ #AHA2025
www.ahajournals.org/doi/10.1161/...

GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis - PubMed Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medicati...

GLP1ra in ADPKD?

pubmed.ncbi.nlm.nih.gov/40815122/

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Hypertension AIM: The “2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults” retires and replaces the “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.” METHODS: A comprehensive literature search was conducted from December 2023 to June 2024 to identify clinical studies, reviews, and other evidence performed on human subjects that were published since February 2015 in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to create a living, working document updating current knowledge in the field of high blood pressure aimed at all practicing primary care and specialty clinicians who manage patients with hypertension.

Before we start, take a look at the guideline itself: www.ahajournals.org/...
Does anyone see the authors?

#nephjc

Check out the insightful VA that makes sense of the updates 🧠
#nephjc
VA by @sejalplakhani.bsky.social

PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit — NephJC This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

Check the insightful #NephJC summary by @msocomd.bsky.social and @salinesolut.bsky.social
They’ve distilled a large, voluminous document into an insightful, well-written, and easily comprehensible resource.📌 You may want to bookmark this as a ready reckoner

PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit — NephJC This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

Change is in the Autumn air 🌬️🍂
Join use only on #Bluesky on 9/16/25 at 9pm EST.
We're discussing the 2025 ACC/AHA Hypertension Guideline Update. 🫀🫘🧠 #NephSky #MedSky
www.nephjc.com/news/accaha2025-klno3

Development of respiratory alkalosis and increased anion gap metabolic acidosis in salicylate poisoning.

Core Curriculum by Biff F. Palmer and Deborah J. Clegg:

Mixed Acid-Base Disturbances: Core Curriculum 2025

bit.ly/Palmer25CC (FREE)

NephJC on Number Needed to Treat (NNT) — NephJC NNT theNNt number needed to treat statistics

The #NephJC version of this here www.nephjc.com/news/2020/10... from @manasib33.bsky.social

#JustSayNo to NNT

The way CV and Kidney Trialists are using NNT in their presentations and papers is disappointing

How to interpret the number needed to treat for clinicians Abstract. The Number Needed to Treat (NNT) is an intuitive tool for evaluating intervention effectiveness, and plays a valuable role in informed medical de

‘The simplicity of the NNT is deceptive and can lead to misinterpretation’

Excellent overview and discussion in @ndt-era.bsky.social academic.oup.com/ndt/advance-... #OpenAccess

I would add: it *does* lead to misinterpretation and should not be used.

#EpiSky #NephSky

Visual abstract

Hepatitis C is associated with GNs - and we are now transplanting kidneys from peeps with Hepatitis C

Good to know incidence if HCV related GN is low www.kidney-international.org/article/S008...

@sumitmohan.bsky.social and colleagues in @kidneyint.bsky.social

#NephSky

In ESRD is spironolactone an overACHIEVEr? — NephJC This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?

Join us 9/2/25 at 9pm EST.
We will discuss the use of spironolactone in patients on dialysis to prevent t cardiovascular outcomes and heart failure hospitalizations.
Invite your friends. #NephJC #NephSky

www.nephjc.com/news/achieve

ACHIEVE: el resumen visual — NephJC ¿La espironolactona será la heroína que conquiste el corazón en hemodiálisis? Descúbrelo en la travesía del ensayo ACHIEVE y únete a la discusión en #NephJC.

🎨 No olviden revisar la versión en español traducida por @dramiliflores.bsky.social
#NephJC

Figure 2. Fully Adjusted Prevalence Ratios (PRs) for Factors Associated With β-Blocker Initiation

Figure 1. Compelling Indication Status Among Veterans Who Initiated a β-Blocker for Hypertension Treatment, 2000 Through 2022

Beta blockers remain overused for #hypertension in the VA (though the tens line is going down, very slowly)

jamanetwork.com/journals/jam... in @jama.com from @jordybc.bsky.social et al

OTOH: I think ESRD should count as a somewhat compelling indication? Almost all HD pts here are on bisoprolol

#NephJC Summer Bookclub: Everything is Tuberculosis by John Green — NephJC The summer book club started in 2015 , with one of the best books we have done in book club, Atul Gawande's Being Mortal . I think it should be required reading for all physicians. So now, in 2025, ...

It's finally here!!
#NephJC summer book club 📚
Everything is Tuberculosis by @johngreensbluesky.bsky.social
8/19/25 @ 9pm EST
Come for the discussion, stay for stories.
www.nephjc.com/news/2025/8/...

#NephJC

#NephJC

Hi, Elba Medina, @elbaonelida.bsky.social , No COIs . March 24th is commemorated in Mexico as Tuberculosis Day, raising awareness about the disease, its prevention, and the importance of early diagnosis and treatment 😷

Hey #NephSky! Welcome to a 🆕 #Skytorial brought to you by @kireports.bsky.social, @isnkidneycare.bsky.social. Our author is @elbaonelida.bsky.social nephrologist at Hospital General de Mexico @hgm_nefrologia. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!

TB deaths from Our World in Data blob:https://ourworldindata.org/9c8bbafc-201d-482c-9f4c-17decf723a36

In the introduction, @johngreensbluesky.bsky.social drops some TB facts

Annually more than a million people die of TB

Overall, more than a *billion* people have died of TB in last 2 centuries

That’s also something like 1 in 7 people who have ever lived 🤯

#NephJCBookClub

📜 For years, phosphate management in dialysis was driven by observational data and expert opinion - not RCTs. Targets were based more on tradition than trial evidence #NephJC

The HiLo Trial - Visual Abstract — NephJC Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis? Check out this crisp VA by Dr Sejal Lakhani

🎨Beautiful visual abstract by @sejalplakhani.bsky.social‬ #NephJC
www.nephjc.com/news/...

Ensayo HiLo: el resumen visual — NephJC Aunque sabemos que el fósforo elevado se asocia consistentemente con mayor mortalidad y eventos cardiovasculares, aún no existe evidencia definitiva de que bajarlo de forma agresiva cambie el pronóstico. Revisemos el resumen visual del estudio HiLo, creado Sejal Lakhani que evaluó objetivos alto

🎨 No olviden revisar la versión en español traducir por @dramiliflores.bsky.social #NephJC
www.nephjc.com/news/...

Hi!, Elba Medina from Mexico City . No COIs #NephJC

👇Read last #NephJCshorts by @hswapnil.medsky.social

✍️On CKD screening cost-efficiency in general population

🎨 Visuals by @nephroseeker.medsky.social

The HiLo Trial - Visual Abstract — NephJC Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis? Check out this crisp VA by Dr Sejal Lakhani

😎Check out the VA for HiLO by @sejalplakhani.bsky.social
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract

High or Low Phosphate? Are we Missing the (P)oint? — NephJC This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?

HiLo, HiLo it's off to work we go! ⛏️
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...

💥Check out the commentary: The Body Speaks Louder Than the Belly: Systemic Inflammation Drives Peritoneal Dialysis Outcomes. 🗣️Thanks a lot @pecoitsfilho & @kireports.bsky.social

🔗 www.kireports.org/cms/10.1016/...